renal-cell carcinoma (advanced) | versus No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
AXIS (Rini), 2011 | axitinib vs sorafenib | PFS 0.67 [0.54; 0.81] | | | Qin, 2012 | axitinib vs sorafenib | | | |
Trial | Treatments | Patients | Method |
---|
AXIS (Rini), 2011 | axitinib (n=-9) vs. (n=-9) | second-line therapy in patients with metastatic renal cell cancer | Sample size: -9/-9 Primary endpoint: FU duration: | Qin, 2012 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|